» Authors » Ismaiel A Tekko

Ismaiel A Tekko

Explore the profile of Ismaiel A Tekko including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 42
Citations 746
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Naser Y, Vora L, Tekko I, Peng K, Volpe-Zanutto F, Greer B, et al.
ACS Appl Mater Interfaces . 2024 Oct; PMID: 39356645
The increasing popularity of prolonged-release dosage forms, owing to their ability to provide continuous drug release after administration, has significantly improved patient compliance and overall quality of life. However, achieving...
2.
Vora L, Tekko I, Volpe Zanutto F, Sabri A, Choy R, Mistilis J, et al.
Pharmaceutics . 2024 Jul; 16(7). PMID: 39065643
Microarray patches (MAPs) offer a noninvasive and patient-friendly drug delivery method, suitable for self-administration, which is especially promising for low- and middle-income country settings. This study focuses on the development...
3.
Vora L, Tekko I, Volpe Zanutto F, Sabri A, Choy R, Mistilis J, et al.
Pharmaceutics . 2024 Jan; 16(1). PMID: 38276512
Microarray patches (MAPs) have shown great potential for efficient and patient-friendly drug delivery through the skin; however, improving their delivery efficiency for long-acting drug release remains a significant challenge. This...
4.
Ramoller I, Volpe-Zanutto F, Vora L, Abbate M, Hutton A, McKenna P, et al.
J Control Release . 2024 Jan; 366:548-566. PMID: 38211640
The lymphatic system possesses the main viral replication sites in the body following viral infection. Unfortunately, current antiretroviral agents penetrate the lymph nodes insufficiently when administered orally and, therefore, cannot...
5.
McKenna P, Abbate M, Vora L, Sabri A, Peng K, Volpe-Zanutto F, et al.
ACS Appl Mater Interfaces . 2023 Jun; 15(26):31300-31319. PMID: 37349320
Transdermal drug delivery is an alternative route of administration that offers avoidance of the associated drawbacks of orally and parenterally administered hydrophobics. However, owing to the extremely specific set of...
6.
Zhang C, Vora L, Tekko I, Volpe-Zanutto F, Peng K, Paredes A, et al.
Int J Pharm . 2023 Jun; 642:123108. PMID: 37301241
Oral administration and intramuscular (IM) injection are commonly recommended options for human immunodeficiency virus (HIV) treatment. However, poor patient compliance due to daily oral dosing, pain at injection sites and...
7.
Naser Y, Tekko I, Vora L, Peng K, Anjani Q, Greer B, et al.
J Control Release . 2023 Mar; 356:416-433. PMID: 36878320
Hydrogel-forming microarray patches (HF-MAPs) are used to circumvent the skin barrier and facilitate the noninvasive transdermal delivery of many hydrophilic substances. However, their use in the delivery of hydrophobic agents...
8.
Hatahet T, Al-Obaidi H, Tekko I, Chen T
Saudi Pharm J . 2022 Oct; 30(9):1283-1292. PMID: 36249939
The Middle East has high youth population; however, it is challenged by uncertain economic situation. Higher education plays a crucial role in the development of nations by equipping generations with...
9.
Moffatt K, Tekko I, Vora L, Volpe-Zanutto F, Hutton A, Mistilis J, et al.
Pharm Res . 2022 Oct; 40(7):1673-1696. PMID: 36224503
Purpose: Whilst significant progress has been made to defeat HIV infection, the efficacy of antiretroviral (ARV) therapy in the paediatric population is often hindered by poor adherence. Currently, two long-acting...
10.
Hamdan I, Tekko I, Bell S
Eur J Pharm Biopharm . 2022 Sep; 179:105-117. PMID: 36067956
Basal cell carcinoma (BCC) is the most common form of skin cancer and responsible for most of the cancer related morbidities and pose a significant public health concern worldwide. Surgery...